The regulators of the multibillion-dollar global drugs industry must sometimes feel like a barnacle on a whale: not easily able to influence the direction of travel. Yesterday's report from the Medicines and Healthcare Products Regulatory Agency (MHRA), on GlaxoSmithKline's failure to disclose adverse evidence about its antidepressant drug Seroxat, reveals again how powerless the watchdog is.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments